Company research
Repare Therapeutics Inc.
CIK 1808158Updated Sep 24, 2026
Filing activity
Latest filing
50 filings on record · SCHEDULE 13G/A, 15-12G, EFFECT, 4, S-8 POS, POS AM.
About the company
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s clinical-stage pipeline includes RP-3467, a Phase 1 Polq ATPase inhibitor; and RP-1664, a Phase 1 PLK4 inhibitor.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 176,506,000Source | 253,901,000Source | 364,075,000Source | 368,715,000Source |
| Property, Plant and Equipment, NetUSD | 2,294,000Source | 4,215,000Source | 4,228,000Source | 5,604,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 84,717,000Source | 111,268,000Source | 159,521,000Source | 334,427,000Source |
| Assets, CurrentUSD | 171,149,000Source | 243,688,000Source | 353,979,000Source | 351,414,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,924,000Source | 3,326,000Source | 5,371,000Source | 7,491,000Source |
| Other Assets, NoncurrentUSD | 179,000Source | 396,000Source | 497,000Source | 586,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 25,375,000Source | 41,819,000Source | 84,558,000Source | 80,294,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 486,674,000Source | 483,350,000Source | 482,032,000Source | 480,699,000Source |
| Retained Earnings (Accumulated Deficit)USD | -417,798,000Source | -333,109,000Source | -239,313,000Source | -210,266,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 54,000Source | 28,000Source | -428,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 151,131,000Source | 212,082,000Source | 279,517,000Source | 288,421,000Source |
| Additional Paid in Capital, Common StockUSD | 82,191,000Source | 61,813,000Source | 37,226,000Source | 17,988,000Source |
| Liabilities and EquityUSD | 176,506,000Source | 253,901,000Source | 364,075,000Source | 368,715,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 25,287,000Source | 39,079,000Source | 78,619,000Source | 35,089,000Source |
| Operating Lease, Liability, CurrentUSD | 1,845,000Source | 2,400,000Source | 2,171,000Source | 1,721,000Source |
| Accounts Payable, CurrentUSD | 3,623,000Source | 2,400,000Source | 461,000Source | 2,302,000Source |
| Operating Lease, Liability, NoncurrentUSD | 88,000Source | 1,010,000Source | 3,257,000Source | 5,592,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -84,689,000Source | -93,796,000Source | -29,047,000Source | -106,908,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 23,170,000Source | 25,063,000Source | 19,691,000Source | 12,829,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 1,229,000Source | 1,934,000Source | -1,348,000Source | 152,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -76,445,000Source | -127,158,000Source | 322,000Source | -85,796,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 49,468,000Source | 78,041,000Source | -175,778,000Source | -1,676,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 0Source | 1,938,000Source | 602,000Source | 1,690,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 542,000Source | 842,000Source | 880,000Source | 95,557,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -26,551,000Source | -48,253,000Source | -174,906,000Source | 8,031,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | 334,427,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,380,000Source | 3,089,000Source | 1,966,000Source | 240,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -116,000Source | 22,000Source | -330,000Source | -54,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 23,160,000Source | 25,063,000Source | 19,691,000Source | 12,829,000Source |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously RecordedUSD | 0Source | 0Source | 0Source | — |
| DepreciationUSD | 1,921,000Source | 1,951,000Source | 1,978,000Source | 1,471,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -2,000Source | -170,000Source | 308,000Source | -144,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | -24,000Source |
| General and Administrative ExpenseUSD | 29,680,000Source | 33,764,000Source | 32,560,000Source | 26,213,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -84,689,000Source | -93,796,000Source | -29,047,000Source | — |
| Income Tax Expense (Benefit)USD | 1,440,000Source | -9,383,000Source | 15,147,000Source | -1,678,000Source |
| Net Income (Loss) Attributable to ParentUSD | -84,689,000Source | -93,796,000Source | -29,047,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -106,908,000Source |
| Nonoperating Income (Expense)USD | 10,274,000Source | 13,045,000Source | 5,896,000Source | 74,000Source |
| Operating ExpensesUSD | 147,000,000Source | 167,357,000Source | 151,626,000Source | 116,260,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 94,288,000Source |
| Proceeds from Stock Options ExercisedUSD | 17,000Source | 153,000Source | 447,000Source | 986,000Source |
| Restructuring CostsUSD | 1,400,000Source | — | — | — |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | 400,000Source | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -93,523,000Source | -116,224,000Source | -19,796,000Source | -108,660,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -83,249,000Source | -103,179,000Source | -13,900,000Source | -108,586,000Source |
| Income Tax Expense (Benefit)USD | 1,440,000Source | -9,383,000Source | 15,147,000Source | -1,678,000Source |
| Net Income (Loss) Attributable to ParentUSD | -84,689,000Source | -93,796,000Source | -29,047,000Source | — |
| Earnings Per Share, BasicUSD per share | -2Source | -2.23Source | -0.69Source | — |
| Earnings Per Share, DilutedUSD per share | -2Source | -2.23Source | -0.69Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 42,411,085Source | 42,093,293Source | 41,922,042Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 42,411,085Source | 42,093,293Source | 41,922,042Source | — |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -2,000Source | -170,000Source | 308,000Source | -144,000Source |
| General and Administrative ExpenseUSD | 29,680,000Source | 33,764,000Source | 32,560,000Source | 26,213,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -88,974,000Source | -108,362,000Source | -17,550,000Source | -110,433,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -84,689,000Source | -93,796,000Source | -29,047,000Source | — |
| Investment Income, NetUSD | 10,391,000Source | 13,334,000Source | 5,631,000Source | 259,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -106,908,000Source |
| Nonoperating Income (Expense)USD | 10,274,000Source | 13,045,000Source | 5,896,000Source | 74,000Source |
| Operating ExpensesUSD | 147,000,000Source | 167,357,000Source | 151,626,000Source | 116,260,000Source |
| Research and Development ExpenseUSD | 115,941,000Source | 133,593,000Source | 119,066,000Source | 90,047,000Source |
| Restructuring CostsUSD | 1,400,000Source | — | — | — |
Filing attachments
d95398dex991.htm · 8-K · 2026-01-28
EX-99.1 2 d95398dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Repare Announces Completion of Acquisition by XenoTherapeutics, Inc. CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) - January 28, 2026 - Repare Therapeutics Inc. (“Repare” or the “Company”) announced today the completion of the previously announced acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno…
Read attachment ↗d14040dex991.htm · 8-K · 2026-01-16
EX-99.1 2 d14040dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) - January 16, 2026 - Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of…
Read attachment ↗d32279dex991.htm · 8-K · 2025-12-29
EX-99.1 4 d32279dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration December 24, 2025 CAMBRIDGE, Mass. & MONTREAL - (BUSINESS WIRE)--Dec. 24, 2025 - Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s …
Read attachment ↗d39095dex991.htm · 8-K · 2025-11-14
EX-99.1 2 d39095dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. - Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 2026 - - Additional portfolio monetization efforts continue - - Company reports 3Q 2025 financial results - - $112.6 million in cash and cash equivalents and marketable securities as of Sept…
Read attachment ↗rptx-ex99_1.htm · 8-K · 2025-08-08
EX-99.1 2 rptx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results Entered into worldwide licensing agreement with Debiopharm for lunresertib Evaluating strategic alternatives to maximize shareholder value Initial data for LIONS and POLAR trials expected to be reported in Q4 2025 $109.5 million in cash and cash equivalents and marketable securities CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) - August 8…
Read attachment ↗d944012dex991.htm · 8-K · 2025-07-16
EX-99.1 2 d944012dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib July 15, 2025 CAMBRIDGE, Mass. & MONTREAL - (BUSINESS WIRE)--Jul. 15, 2025 - Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. (“Debiopharm”), a privately-own…
Read attachment ↗